CASP8 and glioblastoma: These findings not only shed light on genomic mechanisms in GBM resistance to TRAIL-induced apoptosis, but also advise future clinical trials to consider genomic analysis of GBM tumors for identifying CASP8 gene status and utilize it as a genomic marker to predict the responsiveness of GBM to TRAIL therapies.